<DOC>
	<DOCNO>NCT02256592</DOCNO>
	<brief_summary>Even individual treat HIV , chronic immune activation persist associate increase cardiovascular disease , liver disease , mortality . HIV-infected individual imbalance community intestinal microbe think contribute increase persistent inflammation . The purpose study examine safety durability fecal microbiota transplant ( FMT ) , transfer bacterial community stool healthy donor , HIV+ individual anti-retroviral therapy . The study also measure effect FMT immune activation inflammatory biomarkers anti-retroviral treated HIV+ individual .</brief_summary>
	<brief_title>Fecal Microbiota Transplantation HIV</brief_title>
	<detailed_description>Despite antiretroviral therapy ( ART ) , chronic immune activation persist major driver HIV disease progression mortality among HIV-infected individual . Importantly , persistent inflammation strongly associate increase cardiovascular event , accelerate liver disease , impair immunologic recovery ( e.g . low CD4 count , low CD4 CD8 ratio ) , mortality . Therefore , address persistent inflammation remain major goal restore health HIV-infected individual . Novel therapeutic strategy decrease immune activation treat HIV infection need . Marked disruption gut microbial composition , dysbiosis , characteristic HIV-infected individual persist despite long-term ART . Recent study demonstrate relative degree gut microbiome disruption positively correlate inflammatory marker ( IL-6 , kynurenine tryptophan ratio ) . Microbial dysbiosis inflammatory consequence may attractive target intervention decrease immune activation HIV+ individual . Fecal microbiome transplantation ( FMT ) prove durable successful therapeutic strategy gut dysbiosis , treatment recurrent Clostridium difficile infection , restructure composition gut microbiome resemble healthy donor . FMT establish record safety limit adverse effect , even context immunocompromised HIV-infected subject . Donor selection screen conduct OpenBiome . The objective phase I clinical trial establish safety durability FMT HIV+ individual . The microbiome recipient analyze 8 week post FMT evidence engraftment donor microbiome . We examine effect FMT marker immune activation inflammation ART treat HIV-infected individual .</detailed_description>
	<criteria>1 . HIV infect men woman 1875 year age . 2 . On continuous antiretroviral therapy least one year . 3 . Undetectable viral load least one year . 4 . Written inform consent obtain subject ability subject comply requirement study . 1 . CD4 T cell count le 200 cells/mL . 2 . Recent antibiotic use last 3 month . 3 . Pregnant , breastfeeding , unwilling practice birth control participation study . 4 . Presence condition abnormality opinion Investigator would compromise safety patient quality data . 5 . Active GI symptom : inflammatory bowel disease , abdominal pain , hematochezia , symptom require medical evaluation intervention . 6 . Recent hospitalization acute medical condition within precede three month . 7 . Severe comorbidities : cirrhosis , coagulopathy , heart failure , renal failure , respiratory failure . 8 . Testing positive stool screen test : Clostridium difficile toxin PCR , routine bacterial culture enteric pathogen ( E coli , Salmonella , Shigella , Yersinia , Campylobacter ) , culture Vibrio , fecal Giardia antigen , fecal Cryptosporidium antigen , acidfast stain Cyclospora Isospora , ova parasite , stool Rotavirus via EIA . 9 . History anaphylaxis . 10 . Major immunosuppressive medication ( e.g. , calcineurin inhibitor , exogenous glucocorticoid , biological agent , etc . ) systemic antineoplastic agent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>inflammation</keyword>
	<keyword>microbiome</keyword>
	<keyword>immune activation</keyword>
	<keyword>fecal microbiota transplantation</keyword>
	<keyword>dysbiosis</keyword>
</DOC>